Increased oxidative stress in dialysis patients is thought to contribute to increased mortality; however, confirmatory data are scarce. We analyzed the serum concentration of 8-hydroxy-2'–deoxyguanosine (8-OHdG), a marker of oxidative stress, in relation to mortality in hemodialysis (HD) and peritoneal dialysis (PD) patients.
Methods
Serum 8-OHdG, interleukin 6 (IL-6), other biochemical markers, Davies comorbidity score, and protein-energy wasting (PEW) were assessed in 303 prevalent patients treated with HD (n = 220; age: 63 ± 14 years) or PD (n = 83; age: 64 ± 14 years). Mortality was assessed after a median follow-up of 31 months.
Results
The median (25th - 75th percentile) concentration of 8-OHdG was higher in HD than in PD patients: 1.3 ng/mL (0.9 - 1.8 ng/mL) versus 0.5 ng/mL (0.4 - 0.6 ng/mL), p < 0.001. The HD modality (standard β = 0.57, p < 0.001) and dialysis vintage (standard β3 = 0.12, p = 0.02) were independent predictors of serum 8-OHdG in a multivariable linear regression model including age, sex, body mass index, dialysis modality (HD or PD), preceding time on dialysis (dialysis vintage), PEW, comorbidity score, IL-6, and use of angiotensin converting-enzyme inhibitors or angiotensin II receptor blockers or statins. During follow-up, 107 patients died. In multivariable Cox regression models including all 303 patients and adjusted for age, sex, body mass index, dialysis modality, dialysis vintage, and comorbidity score, 8-OHdG was significantly associated with all-cause mortality (adjusted hazard ratio: 1.40; 95% confidence limits: 1.05, 1.87 for 1 standard deviation increase of 8-OHdG). In subgroup analyses according to dialysis modality, 8-OHdG was associated with mortality in HD patients but not in PD patients.
Conclusions
Oxidative stress as assessed by 8-OHdG is an independent predictor of all-cause mortality in dialysis patients. This association was seen in HD patients, but no such association could be demonstrated for PD patients.
EknoyanG.Cardiovascular mortality and morbidity in dialysis patients.Miner Electrolyte Metab1999; 25: 100–4.
2.
CollinsA.J., FoleyR.N., GilbertsonD.T., ChenS.C.The state of chronic kidney disease, ESRD, and morbidity and mortality in the first year of dialysis.Clin J Am Soc Nephrol2009; 4(Suppl 1): S5–11.
3.
VaziriN.D.Oxidative stress in uremia: nature, mechanisms, and potential consequences.Semin Nephrol2004; 24: 469–73.
4.
CarreroJ.J., StenvinkelP.Inflammation in end-stage renal disease—what have we learned in 10 years?Semin Dial2010; 23: 498–509.
5.
HimmelfarbJ., StenvinkelP., IkizlerT.A., HakimR.M.The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia.Kidney Int2002; 62: 1524–38.
6.
GuerinA., PannierB., LondonG.Atherosclerosis versus arterial stiffness in advanced renal failure.Adv Cardiol2007; 44: 187–98.
Del VecchioL., LocatelliF., CariniM.What we know about oxidative stress in patients with chronic kidney disease on dialysis—clinical effects, potential treatment, and prevention.Semin Dial2011; 24: 56–64.
9.
KasaiH., TanookaH., NishimuraS.Formation of 8-hydroxyguanine residues in DNA by X-irradiation.Gann1984; 75: 1037–9.
10.
BeckmanK.B., AmesB.N.Oxidative decay of DNA.J Biol Chem1997; 272: 19633–6.
11.
WuL.L., ChiouC.C., ChangP.Y., WuJ.T.Urinary 8-OHdG: a marker of oxidative stress to DNA and a risk factor for cancer, atherosclerosis and diabetics.Clin Chim Acta2004; 339: 1–9.
12.
TarngD.C., HuangT.P., WeiY.H., LiuT.Y., ChenH.W., Wen ChenT.8-Hydroxy-2'–deoxyguanosine of leukocyte DNA as a marker of oxidative stress in chronic hemodialysis patients.Am J Kidney Dis2000; 36: 934–44.
13.
Mastalerz–MigasA., SteciwkoA., PokorskiM., PirogowiczI., DrobnikJ., BunioA.What influences the level of oxidative stress as measured by 8-hydroxy -2'–deoxyguanosine in patients on hemodialysis?J Physiol Pharmacol2006; 57(Suppl 4): 199–205.
14.
ZoccaliC., Bode–BogerS., MallamaciF., BenedettoF., TripepiG., MalatinoL.Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study.Lancet2001; 358: 2113–17.
15.
BayesB., PastorM.C., BonalJ., ForasterA., RomeroR.Oxidative stress, inflammation and cardiovascular mortality in haemodialysis—role of seniority and intravenous ferrotherapy: analysis at 4 years of follow-up.Nephrol Dial Transplant2006; 21: 984–90.
16.
GrahlD.A., AxelssonJ., NordforsL., HeimbürgerO., BárányP., QureshiA.R.Associations between the CYBA 242C/T and the MPO-463G/A polymorphisms, oxidative stress and cardiovascular disease in chronic kidney disease patients.Blood Purif2007; 25: 210–18.
17.
Kalantar–ZadehK., BrennanM.L., HazenS.L.Serum myeloperoxidase and mortality in maintenance hemodialysis patients.Am J Kidney Dis2006; 48: 59–68.
18.
Marques de MattosA., MarinoL.V., OvidioP.P., JordaoA.A., AlmeidaC.C., ChiarelloP.G.Protein oxidative stress and dyslipidemia in dialysis patients.Ther Apher Dial2012; 16: 68–74.
19.
ZhouQ., WuS., JiangJ., TianJ., ChenJ., YuX.Accumulation of circulating advanced oxidation protein products is an independent risk factor for ischemic heart disease in maintenance hemodialysis patients.Nephrology (Carlton)2012; 17: 642–9.
20.
CastoldiG., AntoliniL., BombardiC., PeregoL., MarianiP., ViganoM.R.Oxidative stress biomarkers and chromogranin a in uremic patients: effects of dialytic treatment.Clin Biochem2010; 43: 1387–92.
21.
Al-HweishA., SultanS.S., MogaziK., ElsammakM.Y.Plasma myeloperoxidase, NT-proBNP, and troponin-I in patients on CAPD compared with those on regular hemodialysis.Hemodial Int2010; 14: 308–15.
22.
SamouilidouE.C., KarpouzaA.P., KostopoulosV., BakirtziT., PanteliasK., PetrasD.Lipid abnormalities and oxidized LDL in chronic kidney disease patients on hemodialysis and peritoneal dialysis.Ren Fail2012; 34: 160–4.
23.
SnædalS., HeimbürgerO., QureshiA.R., DanielssonA., WikstromB., FellstromB.Comorbidity and acute clinical events as determinants of C-reactive protein variation in hemodialysis patients: implications for patient survival.Am J Kidney Dis2009; 53: 1024–33.
24.
TwardowskiZ.J., NolphK.D., KhannaR.Limitations of the peritoneal equilibration test.Nephrol Dial Transplant1995; 10: 2160–1.
25.
DaviesS.J., PhillipsL., NaishP.F., RussellG.I.Quantifying comorbidity in peritoneal dialysis patients and its relationship to other predictors of survival.Nephrol Dial Transplant2002; 17: 1085–92.
26.
QureshiA.R., AlvestrandA., DanielssonA., Divino–FilhoJ.C., GutierrezA., LindholmB.Factors predicting malnutrition in hemodialysis patients: a cross-sectional study.Kidney Int1998; 53: 773–82.
27.
DounousiE., PapavasiliouE., MakedouA., IoannouK., KatopodisK.P., TselepisA.Oxidative stress is progressively enhanced with advancing stages of CKD.Am J Kidney Dis2006; 48: 752–60.
28.
AntonelouM.H., KriebardisA.G., VelentzasA.D., KokkalisA.C., GeorgakopoulouS.C., PapassideriI.S.Oxidative stress– associated shape transformation and membrane proteome remodeling in erythrocytes of end stage renal disease patients on hemodialysis.J Proteomics2011; 74: 2441–52.
29.
HimmelfarbJ., McMonagleE., McMenaminE.Plasma protein thiol oxidation and carbonyl formation in chronic renal failure.Kidney Int2000; 58: 2571–8.
30.
HuhJ.Y., SeoE.Y., LeeH.B., HaH.Glucose-based peritoneal dialysis solution suppresses adiponectin synthesis through oxidative stress in an experimental model of peritoneal dialysis.Perit Dial Int2012; 32: 20–8.
31.
TamuraY., MurayamaT., MinamiM., YokodeM., AraiH.Differential effect of statins on diabetic nephropathy in db/db mice.Int J Mol Med2011; 28: 683–7.
32.
MorinagaH., SugiyamaH., InoueT., TakiueK., KikumotoY., KitagawaM.Effluent free radicals are associated with residual renal function and predict technique failure in peritoneal dialysis patients.Perit Dial Int2012; 32: 453–61.
33.
FuruyaR., KumagaiH., OdamakiM., TakahashiM., MiyakiA., HishidaA.Impact of residual renal function on plasma levels of advanced oxidation protein products and pentosidine in peritoneal dialysis patients.Nephron Clin Pract2009; 112: c255–61.
34.
JiangJ., ChenP., ChenJ., YuX., XieD., MeiC.Accumulation of tissue advanced glycation end products correlated with glucose exposure dose and associated with cardiovascular morbidity in patients on peritoneal dialysis.Atherosclerosis2012; 224: 187–94.
35.
KayaY., AriE., DemirH., SoylemezN., CebiA., AlpH.Accelerated atherosclerosis in haemodialysis patients; correlation of endothelial function with oxidative DNA damage.Nephrol Dial Transplant2012; 27: 1164–9.
36.
IkizlerT.A., MorrowJ.D., RobertsL.J., EvansonJ.A., BeckerB., HakimR.M.Plasma F2-isoprostane levels are elevated in chronic hemodialysis patients.Clin Nephrol2002; 58: 190–7.
37.
SydowK., MunzelT.ADMA and oxidative stress.Atheroscler Suppl2003; 4: 41–51.
38.
YusufS., DagenaisG., PogueJ., BoschJ., SleightP.Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators.N Engl J Med2000; 342: 154–60.
39.
Heart Protection Study Collaborative Group.MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial.Lancet2002; 360: 23–33.
40.
CoombesJ.S., FassettR.G.Antioxidant therapy in hemodialysis patients: a systematic review.Kidney Int2012; 81: 233–46.
41.
BoazM., SmetanaS., WeinsteinT., MatasZ., GafterU., IainaA.Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial.Lancet2000; 356: 1213–18.
42.
TepelM., van der GietM., StatzM., JankowskiJ., ZidekW.The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure: a randomized, controlled trial.Circulation2003; 107: 992–5.
